Combined anti-PD-1 therapy and mTOR inhibition in a melanoma patient with ICI-induced allograft rejection resulted in retained anti-PD-1 tumor efficacy, while promoting tolerance to the allograft (Esfahani et al., 2019). Here, PDCD1 is linked to melanoma.